Skip to main content
Erschienen in: International Cancer Conference Journal 2/2024

14.02.2024 | Case report - Chemotherapy

Complete reduction surgery of a huge recurrent adult granulosa cell tumor after neoadjuvant chemotherapy

verfasst von: Hiroha Tokui, Hideaki Yahata, Yasuhiro Okabe, Naomi Magarifuchi, Shoji Maenohara, Kazuhisa Hachisuga, Hiroshi Tomonobe, Keisuke Kodama, Hiroshi Yagi, Masafumi Yasunaga, Ichiro Onoyama, Kazuo Asanoma, Yoshinao Oda, Masafumi Nakamura, Kiyoko Kato

Erschienen in: International Cancer Conference Journal | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Adult granulosa cell tumors are rare, accounting for only 3–5% of all ovarian tumors. Adult granulosa cell tumors have late recurrences, for which complete resection is an effective option. We report a patient who underwent complete resection of a huge recurrent adult granulosa cell tumor after neoadjuvant chemotherapy. A 72-year-old woman underwent primary surgery for an adult granulosa cell tumor 19 years earlier. A huge recurrent tumor, 11 × 10 cm in size, was noted to elevate the hepatic hilum, inferior vena cava, and right renal vein. The recurrent tumor was too large to resect, thus paclitaxel and carboplatin were administered as neoadjuvant chemotherapy. The tumor shrank to 6 × 5 cm after 6 cycles of chemotherapy, then complete tumor extirpation with resection of the right kidney and temporary scission of inferior vena cava was performed. The patient was alive and well without evidence of a recurrence 1 y postoperatively. Paclitaxel and carboplatin, as neoadjuvant chemotherapy, might be an effective treatment option to achieve complete reduction surgery. This is the first report demonstrating the effectiveness of paclitaxel and carboplatin for huge recurrent adult granulosa cell tumor.
Literatur
1.
Zurück zum Zitat Färkkilä A, Haltia UM, Tapper J et al (2017) Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Ann Med 49:435–447CrossRefPubMed Färkkilä A, Haltia UM, Tapper J et al (2017) Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Ann Med 49:435–447CrossRefPubMed
2.
3.
Zurück zum Zitat Hauptmann S, Friedrich K, Redline R et al (2017) Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch 470(2):125–142CrossRefPubMed Hauptmann S, Friedrich K, Redline R et al (2017) Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch 470(2):125–142CrossRefPubMed
4.
Zurück zum Zitat Mangili G, Sigismondi C, Frigerio L et al (2013) Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study. Gynecol Oncol 130:38–42CrossRefPubMed Mangili G, Sigismondi C, Frigerio L et al (2013) Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study. Gynecol Oncol 130:38–42CrossRefPubMed
5.
Zurück zum Zitat Lee YK, Park NH, Kim JW et al (2008) Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer 18:642–647CrossRefPubMed Lee YK, Park NH, Kim JW et al (2008) Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer 18:642–647CrossRefPubMed
6.
Zurück zum Zitat Yang TM, Chen CH (2022) Early-stage granulosa cell tumor with pelvic recurrence and lung metastasis 16 years later: A case report and review of the literature. Taiwan J Obstet Gynecol 61:118–121CrossRefPubMed Yang TM, Chen CH (2022) Early-stage granulosa cell tumor with pelvic recurrence and lung metastasis 16 years later: A case report and review of the literature. Taiwan J Obstet Gynecol 61:118–121CrossRefPubMed
7.
Zurück zum Zitat East N, Alobaid A, Goffin F et al (2005) Granulosa cell tumour: a recurrence 40 years after initial diagnosis. J Obstet Gynaecol Can 27:363–364CrossRefPubMed East N, Alobaid A, Goffin F et al (2005) Granulosa cell tumour: a recurrence 40 years after initial diagnosis. J Obstet Gynaecol Can 27:363–364CrossRefPubMed
8.
Zurück zum Zitat Plett H, Ricciardi E, Vacaru V et al (2023) Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence. Int J Gynecol Cancer 33:734–740CrossRefPubMed Plett H, Ricciardi E, Vacaru V et al (2023) Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence. Int J Gynecol Cancer 33:734–740CrossRefPubMed
9.
Zurück zum Zitat Inzani F, Santoro A, Travaglino A et al (2022) Prognostic predictors in recurrent adult granulosa cell tumors of the ovary: a systematic review and meta-analysis. Arch Gynecol Obstet 306:315–321CrossRefPubMed Inzani F, Santoro A, Travaglino A et al (2022) Prognostic predictors in recurrent adult granulosa cell tumors of the ovary: a systematic review and meta-analysis. Arch Gynecol Obstet 306:315–321CrossRefPubMed
10.
Zurück zum Zitat Alhusaini H, Elshenawy MA, Badran A et al (2022) Adult-type ovarian granulosa cell tumour: Treatment outcomes from a single-institution experience. Cureus 14:e31045PubMedPubMedCentral Alhusaini H, Elshenawy MA, Badran A et al (2022) Adult-type ovarian granulosa cell tumour: Treatment outcomes from a single-institution experience. Cureus 14:e31045PubMedPubMedCentral
11.
Zurück zum Zitat Thomakos N, Biliatis I, Koutroumpa I et al (2016) Prognostic factors for recurrence in early stage adult granulosa cell tumor of the ovary. Arch Gynecol Obstet 294:1031–1036CrossRefPubMed Thomakos N, Biliatis I, Koutroumpa I et al (2016) Prognostic factors for recurrence in early stage adult granulosa cell tumor of the ovary. Arch Gynecol Obstet 294:1031–1036CrossRefPubMed
12.
Zurück zum Zitat Sehouli J, Drescher FS, Mustea A et al (2004) Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res 24:1223–1229PubMed Sehouli J, Drescher FS, Mustea A et al (2004) Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res 24:1223–1229PubMed
13.
Zurück zum Zitat Homesley HD, Bundy BN, Hurteau JA et al (1999) Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a gynecologic Oncology Group study. Gynecol Oncol 72:131–137CrossRefPubMed Homesley HD, Bundy BN, Hurteau JA et al (1999) Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a gynecologic Oncology Group study. Gynecol Oncol 72:131–137CrossRefPubMed
14.
Zurück zum Zitat Brown J, Shvartsman HS, Deavers MT et al (2005) The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol 97:489–496CrossRefPubMed Brown J, Shvartsman HS, Deavers MT et al (2005) The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol 97:489–496CrossRefPubMed
15.
Zurück zum Zitat Brown J, Shvartsman HS, Deavers MT et al (2004) The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 22:3517–3523CrossRefPubMed Brown J, Shvartsman HS, Deavers MT et al (2004) The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 22:3517–3523CrossRefPubMed
Metadaten
Titel
Complete reduction surgery of a huge recurrent adult granulosa cell tumor after neoadjuvant chemotherapy
verfasst von
Hiroha Tokui
Hideaki Yahata
Yasuhiro Okabe
Naomi Magarifuchi
Shoji Maenohara
Kazuhisa Hachisuga
Hiroshi Tomonobe
Keisuke Kodama
Hiroshi Yagi
Masafumi Yasunaga
Ichiro Onoyama
Kazuo Asanoma
Yoshinao Oda
Masafumi Nakamura
Kiyoko Kato
Publikationsdatum
14.02.2024
Verlag
Springer Nature Singapore
Erschienen in
International Cancer Conference Journal / Ausgabe 2/2024
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-024-00659-5

Weitere Artikel der Ausgabe 2/2024

International Cancer Conference Journal 2/2024 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.